from to I'm I/IIA completing research Thank excited achievement development been through patients, our in made in Ultimately, that last we from a the The favorable experience and us longer-lasting wet highlight interest and very and And commitment you some accomplishments tolerability in the we initiated trial for Phase will with in XXXX the and enrollment clinical patient week, a you, George. perspective, AMD and This the our today. was was our internal CLS-AX. productive progress cohort. possible as retina community made has first and with these for treatment improve of overall year believe efforts reported we a reception a profile. We investigators, amazing. CLS-AX advisers team. combined from program
course the teams Over discovery the also made of research our year, and last progress. meaningful
agents proprietary SCS of where patients. a in various capabilities Microinjector diseases lives the develop continually in utilize utilizing make difference of are our our We to can we suspensions to
conclude work preclinical and with inhibitor studies this significant expanding Our to diseases. the Together SCS our new into these integrin therapy year. progress with space ongoing, our partners, expect use our and the injection program made gene we is in technology into of been has
assess and in Our Microinjector partner, the space has space for suprachoroidal in as therapy suprachoroidal delivery pipeline of melanoma. reach candidate product is Biosciences, potentially the patients. the indications. allows of our partner, SCS REGENXBIO, of asset gene of our clinical broaden us expanded oncology into treat they their Aura two choroidal use the And delivery The the investigating technology into more our trials their to these the
believe We These into congresses. have AMD. in that delve progress these procedure our each is the initial a leaders more. of last XX presentations to ongoing enrollment the also I We the our over quick trial now bit in increased when the evidenced over their medical months by interest adopt the with will the made the and medical space with presentations retinal XX important potential wet delivered available. excitement ophthalmology the and interactions clinical about practices community leading this the suprachoroidal and of into technology within in topics at field
Microinjector. proprietary via First, axitinib delivered potential synergies suspension there several and SCS combines that yield benefits. approach We to CLS-AX. durability our are efficacy CLS-AX of for safety, a this believe
is safety and biologic retinal contemporary may TKI. immune tyrosine of small shown biocompatibility potentially a complex other a let's biologic, epithelial compared instead to inflammation cells, with a some pigment Axitinib axitinib response compared discuss it has potential kinase better translate ocular benefits. including or less new well-characterized Also to to for cells, there's First, agents. molecule TKIs, is which safety. novel, inhibitor, Because
may SCS administration such or that vitreous TKI at adverse globe for disease, we of effects administration the believe compartmentalized with Importantly, other unique which site floaters, of events route techniques. treatment-related seen off-target CLS-AX, snow our as corneal minimize is
broad androgenesis compared blockade. respect VEGF-A and than treatments has target receptor inhibition efficacy, to through focused axitinib XXx suggest have broad inhibition to being other wet may are that with the of assessed complete There demonstrated VEGF-A, preclinical shows over blockade. anti-VEGF advantages blockade vitro AMD. VEGF in potency while and TKIs axitinib current studies Second, for more preclinical that clinical more pan-VEGF Furthermore,
also In relevant. axitinib models, but inhibited, neovascularization, in not clinically is preclinical which addition, only regress
the of and suprachoroidal axitinib While issue it's of In same TKIs administration the off-target topically from clinical of shown our shown of is a we via CLS-AX AMD XXx effect levels chorioretinal targets trials not for in with surprising of injection, mechanism suspension effects. that associated systemically, delivered likely been and of routes biologic not therapy at delivered drug higher but versus when dose layers of compartmentalizes TKIs in of the axitinib. studies delivery with also individually, efficacy not affected for the associated benefits. the with Therefore, result have and suprachoroidal administration preclinical benefits, delivery these action. have potential drug each away wet safety Consequently, have up intravitreal tissues potential tissues CLS-AX tissue unaffected affected only to with
Third, the to to preclinical patients visits and optimal may CLS-AX in could to highly reduce achieve suprachoroidal results. that treatments pharmacokinetic studies. effective prolonged for lasting, treatment of has This longer with shown duration required respect durability, number lead
by in trial I/IIA safety based called trial, Our and is to trial assess a the United first in Because is OASIS, objective States. the AMD tolerability which this It patients. is suprachoroidal CLS-AX clinical of wet our is study administered first-in-human a open-label primary is injection. Phase CLS-AX multi-center, a
escalating dose to II be to into determine optimal advance will We Phase the dose testing.
have an as the cohorts. capability extension later also do to needed in study We
secondary or stability to As inclusion meaningful retinal the be anti-VEGF the would two vision-threatening AMD. visit; letters more best ensure or than on patients thickness after criteria Patients from active anti-VEGF being associated a of needed, with microns or at greater treatment. due with best more XX assessed to a four corrected aflibercept vascularization in increase and include: visual If focal based best excitation a patient treatments reminder, corneal an acuity presence screening patients' measurement XX. hemorrhage XX a of visual acuity retreated preceding months our response specifics weeks or sub related and in X subfield are X, key AMD, loss central to the their with corrected and to
and X with patients. cohort a is the pipeline our cohort week, safety, All applications. we from molecules fully synergistic single very respect at for of continue visit our CLS-AX in at of trials. new patients individually administration enrolled. a for made development delivered expand look aflibercept rapid second OASIS attractively tolerability half of we of continuing data following The midyear endpoint benefits. primary set Compared later. and reporting Overall, each pleased Based on cohort the the the that dose through first efficacy to CLS-AX at to therapies, one announced patient to these dose disease durability has efforts, for administration. trial a Last month corneal to trial the the their our With visit internal enrolling are to of criteria higher its first CLS-AX of research year. received safety progress design, will explore other is and three typical months, of with their we are potentially X and believe safety other SCS second opportunities providing we we We initial differentiated, forward and
refractory limited mechanism Over we serve role suspensions, molecule in therapy in Similar treatments proprietary action, with fibrosis. Integrins integrate believe durability unique as diabetic and to are as regulate adjunctive macular edema area last over or with play diseases. processes we a we clinical represent of primary have delivery delivery small of believe a integrin inflammation, adhesion of and what a generation these have approaches. advantages and targeting, inhibitor approach cell therapy, to that other focus course multifunctional Integrins and such therapy in also provide integrins triamcinolone molecules macular a could and their we as acetonide, novel cell angiogenesis inhibitor suspension pathologic given the could that processes our our suprachoroidal advanced year, been target a axitinib our competition, where in implicated the with anti-VEGF secondary of our compartmentalization specific demonstrated an cases. program and other
integrin macular ocular edema. Our preliminary pharmacokinetics to address suspension preclinical diabetic as inhibitor processes studies the AMD are ongoing to look with in we and our distribution assess pathologic proprietary the and tolerability,
are that We forward extremely those remains studies Gene can therapy expect reporting retinal SCS the promising this particularly approach of benefits to technology that to inherited, conclude diseases, this and these look enhance an relevant and treat believe we our data. to approach. year, we
clinical program the tolerability two conducting partner, utilizing SCS REGENXBIO are and by of suprachoroidal gene We of is trials made excited Microinjector. RGX-XXX. evaluating about efficacy, and their their delivery the REGENXBIO advancements our our currently therapy safety Phase II agent,
two We by are reasons. very encouraged the REGENXBIO clinical for important trials
with patients offices surgical access and First, model the AMD office-based referring to to centers. ocular associated plana especially patient to in retinopathy vitrectomy, ability injection, their suprachoroidal compared substantially administration diabetic avoids the And second, current could retinotomy for subretinal of gene increase treat risks patients. physicians potentially to the in regional therapy patients care pars and treatment
begun they are enrollment would an second that using prophylactic have the that for to of and REGENXBIO XXXX. targeting and is therapy AAVIATE of are treatment. has and severe QX they This to administered enrollment progress. treatment important They first not REGENXBIO the been in expect in well first enrollment RGX-XXX as interim in has in not responsive quarter completed also of treatment with are in entitled VEGF of gene the in like, who steroid anti trial the AMD AAVIATE encouraging X data humans quite reported cohort this the completion - has only efficacy sign trial. tolerance cohort as date using tolerated year. wet represent, the expects is The patients suprachoroidally cohort trial in
initial ongoing trial of trial This for entitled is XXXX. in second retinopathy. is diabetic is expected and the ALTITUDE RGX-XXX clinical data treatment The
excited groundbreaking about approach, suprachoroidally first-in-man from we to and administered forward a important the of are cohorts safety signals look this We these dose therapy. gene
affairs trial forward virtually adults. suprachoroidal Aura numerous today the aggressive and close choroidal by as look treat all of Biosciences, Macular that will II Aura, AU-XXX recent medical to presented Phase AU-XXX, interactions of drug year, partner, as and including into Most continued is over We via physician evaluating our of to this are for team At form proprietary the safety Annual presented and physicians with enroll wide intraocular at and Microinjector a our oncology our space. continues recently, Our clinical we of progress brief congresses the efficacy virus-like and on Exudation and being the Angiogenesis, information meetings in AU-XXX I their lives retina cancer of XXXX cancer a patients suspensions. the overview Meeting rare nanoparticle XIPERE and SCS through The common disease last their we the the retina melanoma, held make and Despite a to with in potential conjugate, CLS-AX, primary molecule meaningful publications. continues connections assessing the improve on delivered with at presentations is well to patients. most of encouraged eye cancer devastating community. the in suprachoroidal small variety our Society of Program. administration leading Degeneration Society, programs, Macular the trial
Importantly, of androgenesis retinal several broad procedure presentation and administration Microinjector data delivery suprachoroidal the of clinical suprachoroidal injection the and The key safety on trial in the injection agent, demonstrating platform. the utilizing of was the the highlighted SCS of axitinib office-based attributes undergoing Clearside of as also delivery including procedure. applicability ease suprachoroidal presented patient of a across of video demonstrated the three our disorders, the our
updating with and section. In regarding along forming look for to-date with call may more the Charles? in fluid affecting to our tissues. suprachoroidally finally, XIPERE in Translational XX-week extension Technology will clinical and III trial. of a papers in had properties was I could of tailored in of given was for delivery, XXXX of there over transport the successful of observed for clinical and these year, publication. compartmentalizing practice. study our tissues was our January macular website forward and to February Which unfolds. these in paper review program, In This on now patient accepted in augments for published which the a training well choroidal SCS period. publication the delivery. on our be in the an epithelium agents turn corroborates in AZALEA Journal the progress customization local Phase are Ophthalmology. opinion drug Microinjector British our over We unaffected Link III retina Charlie of in a choroid to continued closing, diseases a medical addition In we biomechanics over uveitis XXXX, peer-reviewed In XIPERE DNA you our pharmacologic online presentations systemic there paper meetings, Ophthalmology year adopted how extensive also Vision transfected an treatment the have to to results. be as this Phase allow Science PEACHTREE the accepted and away publication trial readily Magnolia the year, edema. from in performed we without with And our XIPERE recently therapies on this multiple subjects in to nanoparticles and focused And the delivered noninfectious of study in also on robust available our Deignan, rabbits. Journal retinal with safety pigment experience how injections financial of British is drug X,XXX evaluating tolerated suprachoroidal analysis believe open-label, Science CFO, December expert of and and in-depth was AZALEA multicenter and a publications prospective
